



March 30, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : *Newspaper publication of advertisements in respect of Basis of Allotment and certain matters relating to the Rights Issue of equity shares of Healthcare Global Enterprises Limited (the "Company") ("Rights Issue").*

Stock Code : *BSE – 539787, NSE – HCG*

Reference : *Regulation 84 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements), 2018 ("SEBI ICDR Regulations").*

In relation to the Rights Issue and further to our letters dated February 24, 2026 and March 06, 2026, we enclose herewith copies of the newspaper advertisements issued by the Company in respect of details of subscription, basis of allotment and credit of fully paid-up equity shares pursuant to Rights Issue etc.,

The aforesaid advertisements have been published today, i.e., March 30, 2026, in compliance with the requirements specified under sub-regulation (1) of Regulation 84 of the SEBI ICDR Regulations, in the following newspapers, with wide circulation:

1. Financial Express – English national daily newspaper;
2. Jansatta – Hindi national daily newspaper; and
3. Vishwavani – Kannada daily newspaper, being the regional language of Bengaluru, where the registered office of the Company is situated.

You are requested to take the above intimation on record.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer
Encl: As above



ZYDUS WELLNESS LIMITED
CIN : L15201GJ1994PLC023490

Regd. Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vashnoodi Circle, Sarkhe-Gandhinagar Highway, Ahmedabad - 382481
Website: www.zyduswellness.com; E-mail: nandish.joshi@zyduswellness.com; Phone No.: +91 79 48040000; +91 79 71800000

NOTICE

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SECURITIES

Notice is hereby given that pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30, 2026 ("SEBI Circular"), a special window has been opened for one year from February 5, 2026 to February 4, 2027, to facilitate transfer and dematerialisation requests of physical securities which were purchased / sold prior to April 1, 2019, including the transfer requests which were rejected / returned / not attended due to deficiency in documents/process or otherwise.

During this period, the securities so transferred shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred / lien-marked / pledged during the said lock-in period.

The eligible investors who wish to avail the benefit of this Special Window facility, are requested to submit required documents as per above-mentioned SEBI Circular, duly complete in all respects, to our Registrar and Share Transfer Agent ("RTA") i.e. MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited), at 5th Floor, 506 to 508, Amarnath Business Centre-I (ABC-I), Nr. St. Xavier's College Corner, Off C G Road, Ellisbridge, Ahmedabad - 380006 on or before February 4, 2027.

For more details, investors may contact the Company at e-mail: nandish.joshi@zyduswellness.com / 079-48040000 or our RTA at e-mail: investor.helpdesk@in.mps.mufg.com / 079-26465179/86/87.

For, Zydus Wellness Limited
Sd/- Nandish P. Joshi
Company Secretary and Compliance Officer
Membership No. : ACS39036

Date : March 28, 2026
Place : Ahmedabad

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.



CAMEO CORPORATE SERVICES LIMITED

"Subramanian Building", No.1, Club House Road, Chennai-600 002.
CIN No: U67120TN1998PLC041613

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SECURITIES

Pursuant to SEBI circular HO/38/13/11(2)2026-MIRSD-POD/ 13750/2026 dated January 30, 2026, investors are informed that, a special window is opened for transfer and dematerialisation of physical securities which were sold/purchased prior to April 01, 2019.

This special window shall be open for a period of one year from February 05, 2026 to February 04, 2027

Investors of our client companies are requested to lodge transfer deed executed prior to April 01, 2019 along with original security certificate(s) and other documents as specified in the aforementioned SEBI circular with the company's Registrar and Share Transfer Agents latest by 4th February, 2027 at the below mentioned address:

Cameo Corporate Services Limited
"Subramanian Building" No.1, Club House Road Chennai - 600 002
Please write to us for any query at https://wisdom.cameoindia.com/.

Place: Chennai
Date: 30.03.2026
For Cameo Corporate Services Limited
Executive Vice President & Company Secretary

PUBLIC NOTICE



VASTU HOUSING FINANCE CORPORATION LTD.
A Limited Company Incorporated under the Companies Act, 1956
Date of Incorporation: 04.02.2005; CIN: U65922MH2005PLC272501,
Registered & Corporate Office: Unit Nos. 203 & 204, 2nd Floor, A wing, Navbharat Estates, Zakaria Bunder Road, Sewri (West), Mumbai - 400015.
Tel No.: 022-24190911; Email: cs@vastuhfc.com; Website: www.vastuhfc.com

CLOSURE OF OFFICE

The office of Vastu Housing Finance Corporation Limited ("Company") situated at Mumbai as mentioned below shall be closed from 30th June, 2026.

Office Address: Unit Nos. 201 and 202, 2nd Floor, A wing, Navbharat Estates, Zakaria Bunder Road, Sewri (West), Mumbai - 400015.

The Premises will remain operational till 29th June, 2026. From 30th June, 2026 onwards, all transactions and correspondence for the Company should be sent to other existing Office address at Central Wing, Second Floor, Navbharat Potteries Old Office Building, Zakaria Bunder Road, Sewri (West), Mumbai - 400015.

In case of any queries, you may contact us at: customercare@vastuhfc.com
Address: Unit Nos. 203 & 204, 2nd Floor, A wing, Navbharat Estates, Zakaria Bunder Road, Sewri (West), Mumbai - 400015.

This advertisement is for information purposes only and neither constitutes an offer or an invitation or a recommendation to purchase, to hold or sell securities nor for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of Offer dated February 24, 2026 (the "Letter of Offer" or "LOF") filed with National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE"), and also filed with the Securities and Exchange Board of India ("SEBI") for information and dissemination on the SEBI's website pursuant to the proviso to Regulation 3 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations")



HEALTHCARE GLOBAL ENTERPRISES LIMITED

HealthCare Global Enterprises Limited ("Company" or "Issuer") was originally incorporated as "Curie Centre of Oncology Private Limited" on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of our Company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. Our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of our Company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006. For details in relation to the changes in name and registered office of our Company, see "General Information" beginning on page 43 of the Letter of Offer dated February 24, 2026 ("LOF").

Registered Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corporate Office: Unity Building Complex, No. 3, Tower Block, Mission Road, Bengaluru 560 027, Karnataka, India
Tel: +91 080 46607700 | Contact Person: Sunu Manuel, Company Secretary and Compliance Officer | E-mail: investors@hcgel.com
Website: www.hcgoncology.com | Corporate Identity Number: L15200KA1998PLC023489



Please scan this QR code to view the Letter of Offer

PROMOTERS OF OUR COMPANY: HECTOR ASIA HOLDINGS II PTE. LTD., CATALYST TRUSTEESHIP LIMITED, AND DR. B.S AJAIKUMAR

ISSUE OF 8,294,566 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹512.00 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹502.00 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹42,468.18 LAKHS ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 1 (ONE) RIGHTS EQUITY SHARE FOR EVERY 17 (SEVENTEEN) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY, MARCH 2, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 72 OF THE LOF.

BASIS OF ALLOTMENT

The Board of Directors of the Healthcare Global Enterprises Limited wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on Wednesday, March 11, 2026 and closed on Wednesday, March 25, 2026 with the last date for on-market renunciation of Rights Entitlements on Friday, March 20, 2026. Out of the total 3,446 Applications for 10,713,388 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA") 185 Applications for 12,945 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 3,261 Applications for 10,700,443 Rights Equity Shares, which was 129.01% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on Friday, March 27, 2026 by the Company, in consultation with the National Stock Exchange of India ("NSE"), the Designated Stock Exchange for the Issue, and the Registrar to the Issue. The Rights Issue Committee of the Company, pursuant to the delegation of authority by the Board of Directors at their meeting held on Friday, March 27, 2026, has approved the allotment of 82,94,566 Right Equity Shares to the successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications after technical rejections have been considered for Allotment.

1. The break-up of valid Applications received through ASBA (after technical rejections) is given below:

Category	No. of Valid Applications Received	No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and Allotted (A+B)
	Number	Number	Number	Number
Eligible Equity Shareholders	3,168	73,26,233	6,69,581	79,95,814
Renounees*	93	2,98,752	0	2,98,752
Total	3,261	76,24,985	6,69,581	82,94,566

* The investors (identified based on DPID & Client ID) whose names did not appear on the list of Eligible Equity Shareholders as on the record date, who held the Rights Entitlements ("REs") as on the Issue Closing Date and have applied for the issue are considered as Renounees.

2. Basis of Allotment:

Category	Applications received		Rights Equity Shares applied for			Rights Equity Shares Allotted		
	Number	%	Number	Value (₹)	%	Number	Value (₹)	%
Eligible Equity Shareholders	3,353	97.30%	1,04,09,150	5,32,94,84,800.00	97.16%	79,95,814	4,09,38,56,768.00	96.40%
Renounees	93	2.70%	3,04,238	15,57,69,856.00	2.84%	2,98,752	15,29,61,024.00	3.60%
Total	3,446	100.00%	1,07,13,388	5,48,52,54,656.00	100.00%	82,94,566	4,24,68,17,792.00	100.00%

The instructions for unblocking of funds were issued to Self-Certified Syndicate Banks (SCSBs) by the Registrar and the listing applications were filed with BSE and NSE both on March 27, 2026. The Dispatch of allotment advice commencing unblocking intimation to the investors, as applicable, will be done after executing the corporate action for credit of Equity shares into the respective demat accounts of the successful allottees on or about March 30, 2026. The trading in fully paid-up Equity Shares issued in the Rights Issue is expected to commence on April 1, 2026, subject to receipt of transfer permissions from NSE and BSE.

Disclaimer clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the LOF has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the LOF. The investors are advised to refer to the LOF for the full text of the Disclaimer clause of the NSE under the heading "Other regulatory and statutory Disclosures- Disclaimer Clause of NSE" on page 70 of the LOF.

Disclaimer clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the letter of offer. The investors are advised to refer to the letter of offer for the full text of the Disclaimer clause of the BSE Limited under the heading "Other regulatory and Statutory Disclosures-Disclaimer Clause of BSE" on page 70 of the LOF.

The investors may contact the Registrar to the Issue in case of any query(ies)/grievance(s) including for credit of rights equity shares and unblocking of funds.

REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 KFintech KFin Technologies Limited 301, The Centrum, 3 rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India. Tel: +91 40 6716 2222/18003094001 E-mail: healthcare.rights@kfintech.com Website: www.kfintech.com Investor grievance e-mail: enward.ris@kfintech.com Contact person: M Murali Krishna SEBI Registration No.: INR00000221	Sunu Manuel , Company Secretary and Compliance Officer HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India; Tel: +91 080 46607700; E-mail: investors@hcgel.com Investor may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-issue or post-issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving complete details such as name, address, contact number(s), e-mail address of the sole/first holder, folio number or demat account of the Applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Form, or the plain paper application, as the case may be, was submitted by the ASBA Investors. For details on the ASBA process, see "Terms of Issue- Making of an Application through the ASBA Process" on page 75 of the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

For HEALTHCARE GLOBAL ENTERPRISES LIMITED
On behalf of the Board of Directors
Sd/-
Sunu Manuel
Company Secretary and Compliance Officer

HEALTHCARE GLOBAL ENTERPRISES LIMITED has filed a Letter of Offer with Stock Exchanges on February 24, 2026. The letter of offer is available on the website of SEBI at www.sebi.gov.in, the website of the stock exchange at www.bseindia.com, www.nseindia.com, the Company website at www.hcgoncology.com and the website of registrar at www.kfintech.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with the SEBI and the stock exchanges, including the section titled "Risk Factors" on Page 24 of the Letter of Offer, for details of the same, when available.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer or sale of securities in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States and will not be, registered under the US Securities Act of 1933, as amended, or an exemption from registration. The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable State Securities Laws. Accordingly, the Rights Equity Shares are only being offered and sold in "Offshore Transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act to eligible equity shareholders, located in jurisdictions where such offer and sale is permitted under the laws of such jurisdictions. The offering to which this Letter of Offer relates is, not, and under no circumstances is to be construed as, an offering of any Rights Entitlements or Rights Equity Shares for sale in the United States or as a solicitation therein of an offer to buy any of the said Securities. Accordingly, you should not forward or transmit the Letter of Offer into the United States at any time.

Aditors 876/26

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Scan this QR code to view the DRHP



Merritronix LTD.
(Formerly known as Merritronix Private Limited)

CIN: U32100TG1988PLC155611

Our Company was incorporated on the October 14, 1988 as "Merritronix Private Limited", a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation issued by the Registrar of Companies, Andhra Pradesh. Subsequently, a Certificate of Registration of Regional Director order, dated October 05, 2021 was issued by the Registrar of Companies pursuant to the shifting of the Registered Office of the Company from the "State of Andhra Pradesh" to the "State of Telangana", under the provisions of the Companies Act, 2013. Thereafter, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an Extraordinary General Meeting held on January 06, 2025, and consequently the name of our Company was changed to "Merritronix LTD.". A Fresh Certificate of Incorporation dated February 07, 2025 was issued by the Registrar of Companies, Central Registration Centre upon such conversion. For further details, please refer to chapter titled "History and Certain Corporate Matters" beginning on Page No. 170 of the Draft Red Herring Prospectus.

Registered Office: C-22, Electronic Complex, Kushaiguda, Hyderabad, Telangana, India, 500062
Telephone: +91 8297912056; E-mail: cs@merritronix.com; Website: <https://www.merritronix.com/>
Contact Person: Ms. Mandava Swathi, Company Secretary & Compliance Officer;

OUR PROMOTERS: MR. DOVARI YESUDAS, MR. DOVARI AMARNATH, MS. VANAJA D, MR. DARSY KETHAN CHANDRA AND MR. DOVARI THAMAN

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE")."

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 47,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MERRITRONIX LTD. (THE "COMPANY" OR "MERRITRONIX" OR "ISSUER") AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE) FOR CASH, AGGREGATING UPTO ₹ [-] LACS ("PUBLIC ISSUE") OUT OF WHICH [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [-] LACS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [-] LACS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [-] % AND [-] % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [-] EDITION OF [-] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [-] EDITION OF [-] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND TELUGU EDITION OF [-]). A TELUGU REGIONAL NEWSPAPER (TELUGU BEING THE REGIONAL LANGUAGE OF TELANGANA WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE BSE LIMITED ("BSE") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE IN ACCORDANCE WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank as applicable.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 (1) and 253 (2) of the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLMs may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"), of which, 40% shall be reserved in the following manner: (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% shall be available for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, states that not less than 35% of the Net Issue shall be available for allocation to individual investors who applies for minimum application size. Not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹ 10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investor shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) (Amendment) Regulations, 2025. All Potential Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled "Issue Procedure" on page 254 of the Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2018 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the Issue and DRHP dated March 26, 2026 which has been filed with the SME Platform of BSE Limited.

Pursuant to SEBI (ICDR) (Amendment) Regulations, 2025 on March 03, 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all additional eligibility criteria, the DRHP filed with the SME Platform of BSE Limited (BSE SME) shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the BSE at <https://www.bseindia.com/> and the website of the Company at <https://www.merritronix.com/> and at the website of BRLM i.e. GYR Capital Advisors Private Limited at <https://gyrcapitaladvisors.com>. Our Company hereby invites the members of the public to give their comments on the DRHP filed with the SME Platform of BSE Limited (BSE SME) with respect to disclosures made in DRHP. The members of the public are requested to send a copy of their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and/or to the BRLM at their respective addresses mentioned below. All comments must be received by BSE, and/or our Company and/or Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the offer on or before 5 p.m. on the 21st day from the aforesaid date of filing the DRHP with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited of the section titled "Risk Factors" beginning on Page No. 22 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 65 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "History and Certain Corporate Matters" beginning on page 170 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGERS	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 GYR Capital Advisors CLARITY TRUST GROWTH GYR CAPITAL ADVISORS PRIVATE LIMITED SEBI Registration Number: INM00012810 Address: 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad-380 054, Gujarat, India. Telephone No: +91 87775 64648 Website: www.gyrcapitaladvisors.com Email ID: merritronix.ipo@gyrcapitaladvisors.in Contact Person: Mr. Mohit Baid	 BIGSHARE SERVICES PRIVATE LIMITED SEBI Registration No.: INR00001385 Address: Office No. S6-2, 6th Floor, Pinnacle Business Park, next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai - 400 093, Maharashtra, India Telephone No: 022-62638200 Website: www.bigshareonline.com Email: www.bigshareonline.com Contact Person: Mr. Rajesh Kumawat	 Ms. Mandava Swathi Address: C-22, Electronic Complex, Kushaiguda, Hyderabad, Hyderabad, Telangana, India, 500062 Tel.: +91 8297912056 E-mail: cs@merritronix.com Website: https://www.merritronix.com/ Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

FOR MERRITRONIX LTD.
ON BEHALF OF THE BOARD OF DIRECTORS
Sd/-
MS. MANDAVA SWATHI
COMPANY SECRETARY AND COMPLIANCE OFFICER

PLACE: Hyderabad
DATE: March 27, 2026

Disclaimer: Merritronix Ltd. is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on March 26, 2026. The Draft Red Herring Prospectus is available on the website of BSE SME at <https://www.bseindia.com/> and is available on the websites of the BRLM at <https://gyrcapitaladvisors.com/offer-documents/> and also on the website of the Company <https://www.merritronix.com/>. Any potential investors should note that investment in equity shares involves a high

This advertisement is for information purposes only and neither constitutes an offer or an invitation or a recommendation to purchase, to hold or sell securities nor for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of Offer dated February 24, 2026 (the "Letter of Offer" or "LOF") filed with National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE"), and also filed with the Securities and Exchange Board of India ("SEBI") for information and dissemination on the SEBI's website pursuant to the proviso to Regulation 3 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations")



HEALTHCARE GLOBAL ENTERPRISES LIMITED

HealthCare Global Enterprises Limited ("Company" or "Issuer") was originally incorporated as "Curie Centre of Oncology Private Limited" on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of our Company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. Our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of our Company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006. For details in relation to the changes in name and registered office of our Company, see "General Information" beginning on page 43 of the Letter of Offer dated February 24, 2026 ("LoF").

Registered Office: HOG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corporate Office: Unity Building Complex, No. 3, Tower Block, Mission Road, Bengaluru 560 027, Karnataka, India
Tel: +91 080 46607700 | Contact Person: Sunu Manuel, Company Secretary and Compliance Officer | E-mail: investors@hcgel.com
Website: www.hogoncology.com | Corporate Identity Number: L15200KA1998PLC023489

PROMOTERS OF OUR COMPANY: HECTOR ASIA HOLDINGS II PTE. LTD., CATALYST TRUSTEESHIP LIMITED, AND DR. B.S AJAIKUMAR

ISSUE OF 8,294,566 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹512.00 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹502.00 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹42,468.18 LAKHS ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 1 (ONE) RIGHTS EQUITY SHARE FOR EVERY 17 (SEVENTEEN) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY, MARCH 2, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 72 OF THE LOF.

BASIS OF ALLOTMENT

The Board of Directors of the Healthcare Global Enterprises Limited wishes to thank all its Equity Shareholders, members and investors for their response to the issue which opened for subscription on Wednesday, March 11, 2026 and closed on Wednesday, March 25, 2026 with the last date for on-market renunciation of Rights Entitlements on Friday, March 20, 2026. Out of the total 3,446 Applications for 10,713,388 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA") 185 Applications for 12,945 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 3,261 Applications for 10,700,443 Rights Equity Shares, which was 129.01% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on Friday, March 27, 2026 by the Company, in consultation with the National Stock Exchange of India ("NSE"), the Designated Stock Exchange for the Issue, and the Registrar to the Issue. The Rights Issue Committee of the Company, pursuant to the delegation of authority by the Board of Directors at their meeting held on Friday, March 27, 2026, has approved the allotment of 82,94,566 Right Equity Shares to the successful Applicants. In the issue, no Rights Equity Shares have been kept in abeyance. All valid Applications after technical rejections have been considered for Allotment.

1. The break-up of valid Applications received through ASBA (after technical rejections) is given below:

Category	No. of Valid Applications Received	No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and Allotted (A+B)
	Number	Number	Number	Number
Eligible Equity Shareholders	3,168	73,26,233	6,69,581	79,95,814
Renounees*	93	2,98,752	0	2,98,752
Total	3,261	76,24,985	6,69,581	82,94,566

* The investors (identified based on DPID & Client ID) whose names did not appear on the list of Eligible Equity Shareholders as on the record date, who held the Rights Entitlements ("REs") as on the Issue Closing Date and have applied for the issue are considered as Renounees.

2. Basis of Allotment:

Category	Applications received		Rights Equity Shares applied for		Rights Equity Shares Allotted	
	Number	%	Number	Value (₹)	Number	Value (₹)
Eligible Equity Shareholders	3,353	97.30%	1,04,09,150	5,32,94,84,800.00	79,95,814	4,09,38,56,768.00
Renounees	93	2.70%	3,04,238	15,57,69,856.00	2,98,752	15,29,61,024.00
Total	3,446	100.00%	1,07,13,388	5,48,52,54,656.00	82,94,566	4,24,68,17,792.00

The instructions for unblocking of funds were issued to Self Certified Syndicate Banks (SCSBs) by the Registrar and the listing applications were filed with BSE and NSE both on March 27, 2026. The Dispatch of allotment advice come unblocking intimation to the investors, as applicable, will be done after executing the corporate action for credit of Equity shares into the respective demat accounts of the successful allottees on or about March 30, 2026. The trading in fully paid-up Equity Shares issued in the Rights Issue is expected to commence on April 1, 2026, subject to receipt of trading permissions from NSE and BSE.

Disclaimer clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the LOF has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the LOF. The investors are advised to refer to the LOF for the full text of the Disclaimer clause of the NSE under the heading "Other regulatory and statutory Disclosures- Disclaimer Clause of NSE" on page 70 of the LOF.

Disclaimer clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the letter of offer. The investors are advised to refer to the letter of offer for the full text of the Disclaimer clause of the BSE Limited under the heading "Other regulatory and Statutory Disclosures-Disclaimer Clause of BSE" on page 70 of the LOF.

The investors may contact the Registrar to the Issue in case of any query(ies)/grievance(s) including for credit of rights equity shares and unblocking of funds.

REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 KFin Technologies Limited 301, The Centrum, 3 rd Floor, 57, Lal Bahadur Shastri Road, Nav Padra, Kuria (West), Kuria, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/18003094001 E-mail: healthcare.rights@kfinitech.com Website: www.kfinitech.com Investor grievance e-mail: einward.ris@kfinitech.com Contact person: M Murali Krishna SEBI Registration No.: INR00000221	Sunu Manuel, Company Secretary and Compliance Officer HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India; Tel: +91 080 46607700; E-mail: investors@hcgel.com Investor may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-issue or post-issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving complete details such as name, address, contact number(s), e-mail address of the sole/first holder, folio number or demat account of the Applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Form, or the plain paper application, as the case may be, was submitted by the ASBA Investors. For details on the ASBA process, see "Terms of Issue- Making of an Application through the ASBA Process" on page 75 of the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

For HEALTHCARE GLOBAL ENTERPRISES LIMITED

On behalf of the Board of Directors

Place: Bengaluru, Karnataka
Date: March 28, 2026

Sd/-
Sunu Manuel
Company Secretary and Compliance Officer

HEALTHCARE GLOBAL ENTERPRISES LIMITED has filed a Letter of Offer with Stock Exchanges on February 24, 2026. The letter of offer is available on the website of SEBI at www.sebi.gov.in, the website of the stock exchange at www.bseindia.com, www.nseindia.com, the Company website at www.hogoncology.com and the website of registrar at www.kfinitech.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer filed with the SEBI and the stock exchanges, including the section titled "Risk Factors" on Page 24 of the Letter of Offer, for details of the same, when available.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer or sale of securities in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States and will not be, registered under the US Securities Act of 1933, as amended, or an exemption from registration. The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable State Securities Laws. Accordingly, the Rights Equity Shares are only being offered and sold in "Offshore Transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act to eligible equity shareholders, located in jurisdictions where such offer and sale is permitted under the laws of such jurisdictions. The Offering to which this Letter of Offer relates is not, and under no circumstances is to be construed as, an Offering of any Rights Entitlements or Rights Equity Shares for sale in the United States or as a solicitation therein of an Offer to buy any of the said Securities. Accordingly, you should not forward or transmit the Letter of Offer into the United States at any time.


AL Factors 876/26

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



(Scan this QR code to view the DRHP)



Merritronix

MERRITRONIX LTD.

(Formerly known as Merritronix Private Limited)
CIN: U32100TG1988PLC155611

Our Company was incorporated on the October 14, 1988 as "Merritronix Private Limited", a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation issued by the Registrar of Companies, Andhra Pradesh. Subsequently, a Certificate of Registration of Regional Director order, dated October 05, 2021 was issued by the Registrar of Companies pursuant to the shifting of the Registered Office of the Company from the "State of Andhra Pradesh" to the "State of Telangana", under the provisions of the Companies Act, 2013. Thereafter, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an Extraordinary General Meeting held on January 06, 2025, and consequently the name of our Company was changed to "Merritronix LTD.". A Fresh Certificate of Incorporation dated February 07, 2025 was issued by the Registrar of Companies, Central Registration Centre upon such conversion. For further details, please refer to chapter titled "History and Certain Corporate Matters" beginning on Page No. 170 of the Draft Red Herring Prospectus.

Registered Office: C-22, Electronic Complex, Kushaiguda, Hyderabad, Telangana, India, 500062
Telephone: +91 8297912056; E-mail: cs@merritronix.com; Website: https://www.merritronix.com/
Contact Person: Ms. Mandava Swathi, Company Secretary & Compliance Officer;

OUR PROMOTERS: MR. DOVARI YESUDAS, MR. DOVARI AMARNATH, MS. VANAJA D, MR. DARSY KETHAN CHANDRA AND MR. DOVARI THAMAN

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE")."

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 47,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MERRITRONIX LTD. (THE "COMPANY" OR "MERRITRONIX" OR "ISSUER") AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE) FOR CASH, AGGREGATING UPTO ₹ [-] LACS ("PUBLIC ISSUE") OUT OF WHICH [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [-] LACS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [-] LACS IS HEREAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [-] % AND [-] % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [-] EDITION OF [-] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [-] EDITION OF [-] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND TELUGU EDITION OF [-], A TELUGU REGIONAL NEWSPAPER (TELUGU BEING THE REGIONAL LANGUAGE OF TELANGANA WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE BSE LIMITED ("BSE") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE IN ACCORDANCE WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank as applicable.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 (1) and 253 (2) of the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLMs may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis (Anchor Investor Portion), of which, 40% shall be reserved in the following manner: (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% shall be available for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, states that not less than 35% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹ 10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investor shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) (Amendment) Regulations, 2025. All Potential Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled "Issue Procedure" on page 254 of the Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2018 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the Issue and DRHP dated March 26, 2026 which has been filed with the SME Platform of BSE Limited. Pursuant to SEBI (ICDR) (Amendment) Regulations, 2025 on March 03, 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all additional eligibility criteria, the DRHP filed with the SME Platform of BSE Limited (BSE SME) shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the BSE at https://www.bseindia.com/ and the website of the Company at https://www.merritronix.com/ and at the website of BRLM I.e. GYR Capital Advisors Private Limited at https://gyrcapitaladvisors.com/. Our Company hereby invites the members of the public to give their comments on the DRHP filed with the SME Platform of BSE Limited (BSE SME) with respect to disclosures made in DRHP. The members of the public are requested to send a copy of their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and/or to the BRLM at their respective addresses mentioned below. All comments must be received by BSE, and/or our Company and/or Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the offer on or before 5 p.m. on the 21st day from the aforesaid date of filing the DRHP with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited to the section titled "Risk Factors" beginning on Page No. 22 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 65 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "History and Certain Corporate Matters" beginning on page 170 of the Draft Red Herring Prospectus.

Investors in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited to the section titled "Risk Factors" beginning on Page No. 22 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 65 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "History and Certain Corporate Matters" beginning on page 170 of the Draft Red Herring Prospectus.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited to the section titled "Risk Factors" beginning on Page No. 22 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 65 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "History and Certain Corporate Matters" beginning on page 170 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGERS	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 GYR CAPITAL ADVISORS PRIVATE LIMITED SEBI Registration Number: INM000012810 Address: 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad -380 054, Gujarat, India. Telephone No: +91 87775 64648 Website: www.gyrcapitaladvisors.com Email ID: merritronix.ipo@gyrcapitaladvisors.in Contact Person: Mr. Mohit Baid	 BIGSHARE SERVICES PRIVATE LIMITED SEBI Registration No.: INR00001385 Address: Office No. S6-2, 6th Floor, Pinnacle Business Park, next to Ahura Centre, Mahakall Caves Road, Andheri East, Mumbai -400 093, Maharashtra, India Telephone No: 022-62638200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Rajesh Kumawat	Ms. Mandava Swathi Address: C-22, Electronic Complex, Kushaiguda, Hyderabad, Hyderabad, Telangana, India, 500062 Tel: +91 8297912056 E-mail: cs@merritronix.com Website: https://www.merritronix.com/ Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-credit of refund orders and non-credit of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

FOR MERRITRONIX LTD.
ON BEHALF OF THE BOARD OF DIRECTORS
Sd/-
MS. MANDAVA SWATHI
COMPANY SECRETARY AND COMPLIANCE OFFICER

PLACE: Hyderabad
DATE: March 27, 2026

Disclaimer: Merritronix Ltd. is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on March 26, 2026. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bseindia.com/ and is available on the websites of the BRLM at https://gyrcapitaladvisors.com/offer-documents/ and also on the website of the Company https://www.merritronix.com/. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 22 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulations under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

THE BIGGEST CAPITAL ONE CAN POSSESS KNOWLEDGE

FINANCIAL EXPRESS
Read to Lead

